Loading stock data…
CHUGAI PHARMACEUTICAL CO (4519.T)
TSE¥6,532-32.00 (-0.49%)
Market ClosedLast close Sep 8
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Chugai Pharmaceutical Co., Ltd. in the Healthcare sector is trading at ¥6,532 with a market capitalization of $11.8T. Wall Street consensus targets ¥9,323 (15 analysts), implying a +42.7% move over the next 12 months. The stock is currently near its 52-week low of ¥6,250, remaining 18.7% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +42.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (JPY) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | ¥1.26T↑ | ¥1.11T↓ | ¥1.17T↓ | ¥1.26T |
| Gross Profit | ¥783.48B↑ | ¥698.06B↓ | ¥831.20B↓ | ¥894.25B |
| Operating Income | ¥533.31B↑ | ¥439.17B↓ | ¥542.00B↓ | ¥598.83B |
| Net Income | ¥374.43B↑ | ¥325.47B↓ | ¥387.32B↓ | ¥434.01B |
Peer Comparison
JNJUNHPFE
Fundamentals
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Ava...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥11.82T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.07
Beta
Defensive asset. Lower volatility than the S&P 500.
0.55
Div Yield
Strong income play. Yield provides a meaningful total return floor.
186.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.49%
Volume
Today's trading volume
2.08M
Recent News
3 Japanese Undervalued Stocks With ROE Over 22%
Japan’s services sector is showing improving growth and contained inflation expectations, which keeps a spotlight on companies that quietly generate steady cash. When macro data calms down, investors often rediscover solid Japanese businesses that already produce cash and carry manageable debt. This article looks at three high quality Japanese stocks that currently appear underappreciated and explains why patient investors may find them interesting today. The stocks covered in this article...
3 Japanese AI Healthcare Stocks Investors May Want To Watch
With governments such as China channeling fresh fiscal spending into healthcare and social security, artificial intelligence in medicine is moving from theory into real projects that need practical solutions. That creates a window for investors who want exposure to AI tools that may help clinicians, hospitals, and researchers work smarter. This article highlights three Transformative AI Healthcare stocks from our screener that show how this theme is taking shape. The three stocks below are a...
Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ...
Travere Therapeutics Inc (TVTX) reports record quarterly revenue of $169.6 million, fueled by a 96% surge in FILSPARI sales and successful FSGS launch momentum.
Major Asian Stock Markets Fall Amid Renewed Middle East Tensions
Major Asian stock markets closed lower Tuesday as new US military strikes on Iran dampened optimism
Earnings Season, Tehran Proposal Lift Asian Stock Markets
Asian stock markets largely gained ground Monday on strength in tech issues, and on media reports th